An Open-label, Randomized, Single-dose, 2X3X3 Partial Replicate, Crossover Study to Compare the Pharmacokinetics and Safety Between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a Fixed Dose Combination of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects

Trial Profile

An Open-label, Randomized, Single-dose, 2X3X3 Partial Replicate, Crossover Study to Compare the Pharmacokinetics and Safety Between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a Fixed Dose Combination of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Amlodipine/fimasartan/rosuvastatin (Primary)
  • Indications Hyperlipidaemia; Hypertension
  • Focus Pharmacokinetics
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 09 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 09 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
    • 20 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top